Research Blog
Retatrutide Research Overview: The Triple Agonist Peptide Researchers Are Watching
For research purposes only. Not for human consumption.
Retatrutide has generated more interest in the peptide research community in the past two years than almost any compound in recent memory. When Phase 2 trial data published in the New England Journal of Medicine in 2023 showed mean body weight reduction exceeding 24% at 48 weeks, the research community took notice.
This post summarizes what the published science shows — the mechanism, the trial data, and why researchers tracking the GLP-1 space have shifted significant attention toward this triple agonist.
What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic peptide developed by Eli Lilly and currently in Phase 3 clinical trials. It functions as a triple agonist — simultaneously activating three receptors:
- GLP-1 receptor (glucagon-like peptide-1)
- GIP receptor (glucose-dependent insulinotropic polypeptide)
- Glucagon receptor
This three-pathway mechanism distinguishes retatrutide from earlier compounds in the GLP space. Semaglutide (Ozempic/Wegovy) is a single GLP-1 agonist. Tirzepatide (Mounjaro/Zepbound) is a GLP-1 + GIP dual agonist. Retatrutide adds glucagon receptor activation — a third axis that research suggests drives meaningfully higher energy expenditure.
The Mechanism: Why the Glucagon Axis Matters
GLP-1 and GIP receptor agonism are well-characterized in the literature: reduced appetite, slowed gastric emptying, improved insulin sensitivity. These pathways explain most of semaglutide’s and tirzepatide’s observed effects.
The glucagon component is where retatrutide’s research profile diverges.
Glucagon receptor activation increases hepatic glucose output and thermogenic fat oxidation — effects that traditionally work against metabolic goals when glucagon is elevated in isolation. But in the context of balanced GLP-1/GIP signaling, researchers hypothesize the glucagon axis instead enhances energy expenditure without triggering compensatory glucose dysregulation.
The net effect observed in trials: more fat mass reduction, more preserved lean mass relative to total weight lost, and a higher overall percentage reduction compared to dual-agonist protocols.
Phase 2 Trial Data (Jastreboff et al., NEJM 2023)
The key study: “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial” (Jastreboff AM et al., New England Journal of Medicine, 2023).
Design: Randomized, double-blind, placebo-controlled. 338 adults with obesity (BMI ≥30 or ≥27 with comorbidities). 48-week treatment period.
| Dose | Mean Weight Reduction (48 wks) |
|---|---|
| 1 mg weekly | ~8.7% |
| 4 mg weekly | ~17.5% |
| 8 mg weekly | ~22.8% |
| 12 mg weekly | ~24.2% |
| Placebo | ~2.1% |
The 12mg cohort showed a 24.2% mean reduction — a figure that exceeded any published data from tirzepatide Phase 2/3 trials at equivalent duration.
Secondary endpoints: Reductions in waist circumference, improvements in cardiometabolic markers (triglycerides, blood pressure, fasting glucose), and favorable lipid panel shifts were observed across dose cohorts.
Safety profile in trial: Most common adverse events were gastrointestinal (nausea, vomiting, diarrhea) — consistent with the GLP-1 class. No unexpected safety signals were identified in Phase 2. Phase 3 safety data is ongoing.
Retatrutide vs Tirzepatide: What the Research Shows
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Phase 3 max weight reduction | ~22.5% (SURMOUNT-1) | Phase 3 data pending |
| Phase 2 max weight reduction | ~20.9% | ~24.2% |
| FDA approval status | Approved (Zepbound, Mounjaro) | Phase 3 (as of 2024) |
| Lean mass preservation | Strong | Preliminary data favorable |
Current Research Status
As of mid-2026, Phase 3 trials (TRIUMPH program) are ongoing across multiple metabolic endpoints. No FDA approval as of this writing — retatrutide remains in active development.
Why Researchers Source Retatrutide
The Phase 2 data has driven significant interest from researchers studying GLP-1/GIP/glucagon receptor biology, metabolic disease models, and obesity pharmacology. Purity and source reliability matter critically in research contexts. COA-verified, HPLC-tested material with confirmed molecular weight is the baseline requirement for reproducible results.
View Retatrutide 20mg →
View Retatrutide 30mg →
All products are for research purposes only. Not for human consumption. Alpha Peptides US provides Certificate of Analysis documentation for all SKUs.
References
- Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity.” N Engl J Med. 2023;389:514-526.
- Frías JP, et al. “Tirzepatide versus Semaglutide Once Weekly.” N Engl J Med. 2021;385:503-515.
- Eli Lilly. ClinicalTrials.gov: TRIUMPH Phase 3 Program.